Morphosys
Presence
Morphosys is one of the...
Morphosys is a company listed under the stock ticker MPSYY (DE).
Morphosys has a direct presence in 2 countries.
Executives
View the org chart displaying its 25 main executives
Most searched biographies at Morphosys
- Jean-Paul Kress, Chief Executive Officer
- George Golumbeski, Deputy Chairman
- Krisja Vermeylen, Director
Create your alert
to follow the executive moves at Morphosys.
Pharmaceuticals
Morphosys has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Morphosys
- MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
- MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
- Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
- MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
- Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
- MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
- View more press releases Close
Social media about Morphosys
- Morphosys on Wikipedia, Google News & Yahoo Finance
- Morphosys on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including George Golumbeski 
